Press Release
Digbi Health in the news
Featured Press
Gulf Coast Regional Blood Center selects Digbi Health to Elevate Employee Health Programs for Weight Management, Diabetes, and Digestive Issues
Palo Alto, California, Feb 15, 2024 - Digbi Health, an innovator in personalized health technology, is proud to announce its new collaboration with Gulf Coast Regional Blood Center, a key blood provider in Houston and surrounding counties. This partnership is set to revolutionize employee health management by integrating personalized health solutions based on advanced genetics and gut biome analysis into the wellness programs of a critical healthcare provider. Enhancing Employee Wellness at Gulf Coast Regional Blood Center The Gulf Coast Regional Blood Center team will benefit from Digbi Health's comprehensive health platform to optimize weight management and mitigate physical and mental health challenges. By leveraging precision biology through detailed genetics and gut microbiome analysis, this initiative perfectly aligns with the center's dedication to fostering the health and well-being of its employees and the communities they serve. The program specifically addresses chronic conditions such as obesity, type 2 diabetes, and digestive disorders, benefiting employees and their families. A Strategic Collaboration to Enhance Community Health Digbi Health's tailored health approach is strategically aligned with the Gulf Coast Regional Blood Center’s core mission of community partnership to save and sustain lives, beginning with its workforce. This collaboration is poised to enrich the center's employee wellness program, establishing a new benchmark for employee care within the life-saving operations of the blood center. Ranjan Sinha, CEO of Digbi Health, said on the collaboration, "This partnership is a milestone for us at Digbi Health. It embodies our commitment to transform individual chronic care by decoding our genetics, gut biome, and blood markers.“ About Gulf Coast Regional Blood Center Founded in 1975, Gulf Coast Regional Blood Center is an independent, nonprofit organization committed to ensuring a safe and reliable blood supply. With over 650 employees, Gulf Coast Regional Blood Center serves a vast area across Texas, including 26 counties. About Digbi Health Digbi Health specializes in genetics, gut microbiome, and digital health technologies to redefine personalized healthcare. Their platform is designed to reduce medication dependence and healthcare costs, particularly in chronic illness management. For more information, media inquiries, or interviews, please contact: partner@digbihealth.com This contract underscores Digbi Health's commitment to expanding personalized healthcare nationwide.
Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity
PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit™ uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™ is based on recognition by the National Institutes of Health (NIH) and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions. True Personalization: The 5-Point Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe, sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com
Digbi Health - WVU in a research partnership to explore the relationship between personalized postoperative weight loss, genetics, and the gut microbiome
At Digbi Health, we continue to look for better solutions in personalized wellness and care. To this effect, we are proud to announce an upcoming research collaboration with The West Virginia University Medicine Medical and WVU Bariatrics Surgical Weight-Loss Program. The study will utilize Digbi Health’s personalized digital therapeutics platform to better understand the role of the gut microbiome and human genetics in postoperative weight loss and maintenance. The clinical pilot will evaluate the effectiveness of Digbi Health’s obesity management digital program personalized to each bariatric surgery patient, one-year post sleeve gastrectomy. It will be fine-tuned based on the patient’s lifestyle, genetics, and gut microbiome risks to assist with weight loss as well as maintaining a healthy weight. Through this collaboration with WVU Medical, we aim to further explore the critical importance of personalized nutrition and its direct impact on people suffering from obesity and associated metabolic illnesses. A long-term solution for Obesity Obesity is a complex metabolic disease and an ongoing global epidemic, with associated inflammatory, digestive, musculoskeletal, skin morbidities. Moreover, it is a risk factor for diabetes, cardiovascular disease, COVID-19, and could lead to reduced life expectancy. Bariatric surgery is an effective long-term intervention for morbid obesity. Yet, to reap the best outcomes from bariatric surgery, the patients need to make lifelong healthy changes in eating patterns. Social support is also a major factor in making the changes stick. Research indicates that individuals’ genetic and gut microbiome are intrinsically linked to their metabolism. Digbi Cares’ personalized meal plans and nutrition guidelines are curated to an individual’s genetic and gut microbiome markers, thus contributing to successful post-op weight loss and helping with weight maintenance. Nova Szoka MD, FACS, FASMBS, Assistant Professor at J.W. Ruby Memorial Hospital, WVU Bariatrics Surgical Weight-Loss Center is the principal investigator of the study. Dr. Skoza has said that “WVU Bariatrics is excited to partner with Digbi Health to better understand how genomic, gut microbiome, and metabolomic factors can contribute to successful weight loss following bariatric surgery.”
Latest Press
Gulf Coast Regional Blood Center selects Digbi Health to Elevate Employee Health Programs for Weight Management, Diabetes, and Digestive Issues
Palo Alto, California, Feb 15, 2024 - Digbi Health, an innovator in personalized health technology, is proud to announce its new collaboration with Gulf Coast Regional Blood Center, a key blood provider in Houston and surrounding counties. This partnership is set to revolutionize employee health management by integrating personalized health solutions based on advanced genetics and gut biome analysis into the wellness programs of a critical healthcare provider. Enhancing Employee Wellness at Gulf Coast Regional Blood Center The Gulf Coast Regional Blood Center team will benefit from Digbi Health's comprehensive health platform to optimize weight management and mitigate physical and mental health challenges. By leveraging precision biology through detailed genetics and gut microbiome analysis, this initiative perfectly aligns with the center's dedication to fostering the health and well-being of its employees and the communities they serve. The program specifically addresses chronic conditions such as obesity, type 2 diabetes, and digestive disorders, benefiting employees and their families. A Strategic Collaboration to Enhance Community Health Digbi Health's tailored health approach is strategically aligned with the Gulf Coast Regional Blood Center’s core mission of community partnership to save and sustain lives, beginning with its workforce. This collaboration is poised to enrich the center's employee wellness program, establishing a new benchmark for employee care within the life-saving operations of the blood center. Ranjan Sinha, CEO of Digbi Health, said on the collaboration, "This partnership is a milestone for us at Digbi Health. It embodies our commitment to transform individual chronic care by decoding our genetics, gut biome, and blood markers.“ About Gulf Coast Regional Blood Center Founded in 1975, Gulf Coast Regional Blood Center is an independent, nonprofit organization committed to ensuring a safe and reliable blood supply. With over 650 employees, Gulf Coast Regional Blood Center serves a vast area across Texas, including 26 counties. About Digbi Health Digbi Health specializes in genetics, gut microbiome, and digital health technologies to redefine personalized healthcare. Their platform is designed to reduce medication dependence and healthcare costs, particularly in chronic illness management. For more information, media inquiries, or interviews, please contact: partner@digbihealth.com This contract underscores Digbi Health's commitment to expanding personalized healthcare nationwide.
Digbi Health Launches GLP-Fit™ Program: Expands its Precision Biology Platform to Incorporate GLP-1 based Personalized Care for Obesity
PALO ALTO, Calif., September 28, 2023 – (BUSINESS WIRE)-- Digbi Health, the leader in precision biology-based telehealth care for three of the top four healthcare costs - Obesity, T2D, and Digestive Health - announced today the launch of its latest innovation in obesity care, Digbi GLP-Fit™, a scientifically-backed approach to identify the best treatment path for an individual to prevent and treat obesity. Key Highlights: Digbi GLP-Fit™ uses the science of precision biology to identify the best treatment path for obesity for an individual with 87% accuracy, which may include 1) only precision nutrition, 2) a combination of precision nutrition and lower-cost drugs like Metformin, or 3) a combination of precision nutrition and GLP-1 medications. For Pharmacy Benefit Managers (PBMs), Digbi GLP-Fit™ streamlines prior authorization processes for GLP-1 obesity management drugs, eliminating member frustration, generating multi-million dollar savings, and creating goodwill for health plans and employers. Digbi GLP-Fit™ program guarantees 100% financial ROI, providing immediate and tangible savings for employers, PBMs, and health plans, all while ensuring optimal and medically safe patient care. The Science Behind Digbi GLP-Fit(™) This clinically proven approach integrates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) insights to recommend the best path for care and deliver personalized, clinically effective obesity treatment programs. Unlike other digital programs that rely exclusively on behavior change, Digbi GLP-Fit™ is based on recognition by the National Institutes of Health (NIH) and medical research institutions like Harvard Health that genetics account for up to 80% of the risk of obesity and that an individual's insulin resistance and gut-microbiome are essential factors in addressing obesity. Digbi GLP-Fit™ integrates telehealth and precision nutrition based on genetics, gut microbiome, and insulin metabolism. Sustainable, Effective, and High-Quality Care This personalized approach offers tremendous savings for employers and payers. Digbi's program ensures that individuals are not unnecessarily on lifelong GLP-1 treatments, aligning with Digbi Health's prevention and effective care mission. With a Google rating of 4.8 stars, Digbi Health stands out for its unwavering commitment to delivering a high-quality member experience. "We believe in the power of precision biology and full-spectrum obesity care, which includes anti-obesity medications only when necessary. Recognizing that everyone does not respond the same way to food and medicine, Digbi is committed to making obesity care personalized, preventive, and holistic," said Ranjan Sinha, CEO of Digbi Health. "Payers and employers want to partner with us because our unique approach delivers the best obesity solution that is clinically safe and financially sustainable.” Novo Nordisk's Global Prevention Accelerator Program recently selected Digbi to pilot-test solutions for preventing obesity and related cardiometabolic conditions. True Personalization: The 5-Point Digbi GLP-Fit™ Program Difference While other digital providers tout personalization, Digbi GLP-Fit delivers the following advanced capabilities: Precision Diagnostics: Incorporates genetics, gut microbiome, and Continuous Glucose Monitoring (CGM) to provide a comprehensive bio-digital twin view of an individual's health. Risk Assessment: Evaluate the patient's obesity risk embedded in their genetics, gut microbiome, and insulin metabolism. Three hundred gene variants are used to develop and monitor a polygenic risk score for weight regain. Precision Biology-Based Lifestyle Support: The FDA requires GLP drugs to have nutrition and lifestyle support. Proven and Patented De-prescription Path: Develops clinically safe, sustainable, personalized tapering off-plan for GLP drugs. Gut Microbiome Informed Care: GLP is a gut hormone that regulates appetite, metabolism, and insulin secretion. Recent studies have shown that the gut microbiome may play a role in the effectiveness of GLP-1 drugs. With Digbi GLP-Fit™, the gut microbiome is monitored every 120 days. A longer tapering period is considered if the gut microbiome has not shifted to a less obesogenic state. Media Contact: Beverly Ibarrolan; beverly@digbihealth.com About Digbi Health Digbi Health is leading through innovation, offering a holistic solution for treating Obesity, Cardiometabolic, and Digestive disorders—three of healthcare's top 4 costly conditions. Our Precision Biology approach uses genetics, gut microbiome, Abbott CGM, and pharmaceuticals only when necessary to create personalized care programs that slash medication dependency and healthcare costs. We are on a mission to make chronic illness optional. Learn more at: www.digbihealth.com
Digbi Health - WVU in a research partnership to explore the relationship between personalized postoperative weight loss, genetics, and the gut microbiome
At Digbi Health, we continue to look for better solutions in personalized wellness and care. To this effect, we are proud to announce an upcoming research collaboration with The West Virginia University Medicine Medical and WVU Bariatrics Surgical Weight-Loss Program. The study will utilize Digbi Health’s personalized digital therapeutics platform to better understand the role of the gut microbiome and human genetics in postoperative weight loss and maintenance. The clinical pilot will evaluate the effectiveness of Digbi Health’s obesity management digital program personalized to each bariatric surgery patient, one-year post sleeve gastrectomy. It will be fine-tuned based on the patient’s lifestyle, genetics, and gut microbiome risks to assist with weight loss as well as maintaining a healthy weight. Through this collaboration with WVU Medical, we aim to further explore the critical importance of personalized nutrition and its direct impact on people suffering from obesity and associated metabolic illnesses. A long-term solution for Obesity Obesity is a complex metabolic disease and an ongoing global epidemic, with associated inflammatory, digestive, musculoskeletal, skin morbidities. Moreover, it is a risk factor for diabetes, cardiovascular disease, COVID-19, and could lead to reduced life expectancy. Bariatric surgery is an effective long-term intervention for morbid obesity. Yet, to reap the best outcomes from bariatric surgery, the patients need to make lifelong healthy changes in eating patterns. Social support is also a major factor in making the changes stick. Research indicates that individuals’ genetic and gut microbiome are intrinsically linked to their metabolism. Digbi Cares’ personalized meal plans and nutrition guidelines are curated to an individual’s genetic and gut microbiome markers, thus contributing to successful post-op weight loss and helping with weight maintenance. Nova Szoka MD, FACS, FASMBS, Assistant Professor at J.W. Ruby Memorial Hospital, WVU Bariatrics Surgical Weight-Loss Center is the principal investigator of the study. Dr. Skoza has said that “WVU Bariatrics is excited to partner with Digbi Health to better understand how genomic, gut microbiome, and metabolomic factors can contribute to successful weight loss following bariatric surgery.”
